MEDOPRED Solution for injection / infusion Ref.[28364] Active ingredients: Prednisolone

Source: Υπουργείο Υγείας (CY)  Revision Year: 2021  Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus

4.1. Therapeutic indications

For systemic therapy:

Injectable glucocorticoids are indicated in the following cases, especially when oral therapy is not possible or desirable.

Rheumatic disorders:

Some cases or specific forms (Felty, Sjogren) of rheumatoid including

  • juvenile rheumatoid arthritis;
  • acute rheumatism;
  • lupus erythematosus disseminatus;
  • polyarteritis nodosa;
  • temporal arteritis (polymyalgia rheumatica);
  • poly* and dermatomyositis.

Pulmonary disorders:

  • chronic obstructive pulmonary disease (COPD);
  • sarcoidosis;
  • status asthmaticus;
  • chronic asthmatic bronchitis;
  • allergic pulmonary diseases, such as famer’s lung disease and pigeon breeder’s lung disease, Lőffler’s syndrome;
  • aspiration pneumonitis;
  • cryptogenic fibrosing alveolitis.

Gastroenterological disorders:

For treatment during the critical stage in case of:

  • ulcerative colitis, rectal only;
  • regional enteritis (Crohn’s disease);
  • certain forms of hepatitis.

Haematological disorders:

  • autoimmune hemolytic anemia;
  • idiopathic thrombocytopenic purpura;
  • reticulolymphoproliferative disorders (see also under oncological disorders).

Renal disorders:

  • nephrotic syndrome, especially as part of lupus erythematosus.

Endocrine disorders:

  • congenital adrenal hyperplasia in cases where sodium retention occurs. In most cases of congenital adrenal hyperplasia, a loss of sodium occurs to a greater or lesser extent and hydrocortisone or cortisone is generally preferred;
  • endocrine exophthalmos.

Oncological disorders:

  • lymphatic leukemia, especially acute forms;
  • malignant lymphoma: Hodgkin’s disease, Non-Hodgkin’s lymphoma;
  • metastased breast cancer;
  • hypercalcemia as a result of bone metastases or Kahler’s disease;
  • Kahler’s disease.

Neurological disorders:

  • acute exacerbations of multiple sclerosis;
  • cerebral edema resulting from brain metastases.

Ocular disorders:

  • chorioretinitis;
  • iridocyclitis;
  • optic neuritis;
  • temporal arteritis;
  • orbital pseudotumor.

Skin disorders:

  • pemphigus vulgaris and bullous pemphigoid;
  • erythrodermas;
  • serious forms of erythema multiforme (Stevens-Johnson syndrome);
  • mycosis fungoides;
  • bullous dermatitis herpetiformis.

Miscellaneous:

  • intense allergic and anaphylactic reactions;
  • as immunosuppressant in organ transplantation;
  • as an adjuvant in the prevention of nausea and vomiting and in the treatment of cancer with oncolytics that have a serious emetic effect.

For local therapy:

  • inflammatory articular and peri-articular disorders.

4.2. Posology and method of administration

Method of administration

The solution can be administered by intravenous, subcutaneous, intramuscular, intra-articular or periarticular injection, or given after dilution by enema.

Intravenous injections of high doses should be given slowly over a period of 3-5 minutes.

Intra-articular and periarticular injections should be given under strict aseptic conditions, as glucocorticoids decrease the resistance to infections.

Posology

Subcutaneous or intramuscular injection

In general, glucocorticoid dosage depends on the severity of the condition and the response of the patient. Under certain circumstances, for instance in stress and changed clinical picture, dose adjustments may be necessary. As an initial dosage, a daily injection of 25 mg is usually sufficient (corresponding to 0.85ml of Medopred). This dosage is maintained or increased if needed until a satisfactory reaction is obtained. If no favourable response is obtained within a few days, continuation of therapy is undesirable. As soon as symptoms diminish, gradual dosage reduction should be attempted, while maintaining the therapeutic result, and if possible switching to an oral glucocorticoid therapy, preferably one administration in the morning or one administration per 48 hours (alternate therapy). A continuous attempt should be made to further reduce the dosage or taper it off completely. After prolonged treatment, discontinuation of the therapy should be very gradual. This reduces the probability of relapse, restricts complications and allows recovery of the suppressed hypothalamic-pituitary-adrenal system (therefore less risk of adrenal insufficiency).

Intravenous injection

For acute, life-threatening situations (e.g. strong anaphylactic reactions, acute severe asthma) higher dosages up to 125 mg may be needed (corresponding to 4.2ml of Medopred).

Intra-articular or periarticular injection

Dosage depends on the size of the joint or periarticular space and on the severity of symptoms. In general, one injection of 25 mg is sufficient (corresponding to 0.85ml of Medopred). If necessary, the injection may be repeated. Sometimes, one or more injections of 10-15mg can be effective (corresponding to 0.3ml-0.5ml of Medopred).

Through an enema in patients with ulcerative colitis

25 mg diluted in 120 ml normal saline (corresponding to 0.85ml of Medopred).

4.9. Overdose

There is no clinical picture of acute overdose with a glucocorticoid.

Glucocorticoids are dialysable.

6.3. Shelf life

24 months.

6.4. Special precautions for storage

Store below 25°C, in the original package. Do not refrigerate or freeze.

6.5. Nature and contents of container

Glass type I, brown ampoules, containing 1ml of the solution, labelled and packed in a card cartons of 10 or 100 ampoules.

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

For parenteral administration.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.